Podcasts about covid-19 vaccine

This week's episode covers the effectiveness of a fixed-dose albuterol-budesonide combination for asthma, new findings on Nerodomelast for progressive pulmonary fibrosis, the FDA's endorsement of a new COVID-19 vaccine targeting the JN.1 lineage, and insights into extended-phase anticoagulation for pediatric venous thromboembolism.

On this day ... The Golden Gate Bridge opens. This week, as we mark the anniversary of a historic Everest summit, we take a closer look at a new strategy to climb the world's tallest peak. The latest on Russia & Ukraine; Israel & Hamas, and King Charles in Canada. What To Know: What happens next with the spending bill. New recommendation on COVID-19 vaccines. Helpful Links: "All-In" Podcast Everest Climb SUPPORT OUR MISSION: Love nonpartisan news? Want a bigger serving of the serious headlines?  Here's how you can become a SCOOP insider: https://www.scoop.smarthernews.com/get-the-inside-scoop/    Shop our gear!  Instagram: https://www.instagram.com/smarthernews/  Website: https://smarthernews.com/  YouTube Channel: https://www.youtube.com/smarthernews 

A quick update on several controversial new items including a proposed reality show for citizenship, a $400 million plane gift from Qatar to the Pentagon, new FDA recommendations regarding COVID-19 vaccine boosters, and the latest on the "big, beautiful bill."   SUPPORT OUR MISSION: Love nonpartisan news? Want a bigger serving of the serious headlines?  Here's how you can become a SCOOP insider: https://www.scoop.smarthernews.com/get-the-inside-scoop/    Shop our gear!  Instagram: https://www.instagram.com/smarthernews/  Website: https://smarthernews.com/  YouTube Channel: https://www.youtube.com/smarthernews 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##FDA Approves New Cancer DrugThe FDA has approved a new cancer drug that has shown promising results in clinical trials. This drug is expected to provide a much-needed treatment option for patients with this type of cancer.##Major Biotech Company Announces MergerA major biotech company has announced a merger with another company in the industry. This merger is expected to create a powerhouse in the biotech world, with the potential for groundbreaking research and development.##COVID-19 Vaccine UpdateThere have been new developments in the race for a COVID-19 vaccine. Several pharmaceutical companies are in the final stages of clinical trials, and there is hope that a vaccine will be available soon.##Drug Pricing Legislation PassesLegislation aimed at addressing drug pricing has passed in Congress. This legislation is expected to lower the cost of prescription drugs for consumers and improve access to affordable medication.##Biotech Startup Receives FundingA promising biotech startup has secured funding to further its research and development efforts. This funding will allow the company to continue its work on innovative therapies and treatments.##FDA Issues Warning About Opioid UseThe FDA has issued a warning about the dangers of opioid use. This warning comes amid a growing opioid crisis in the United States, and highlights the importance of safe prescribing practices.##New Gene Therapy Shows PromiseA new gene therapy has shown promise in treating a rare genetic disorder. This therapy has the potential to revolutionize treatment for patients with this condition, offering hope for improved outcomes.##Pharma Company Launches Patient Assistance ProgramA pharmaceutical company has launched a patient assistance program to help those in need access necessary medications. This program aims to provide support for patients facing financial barriers to treatment.##Biotech Breakthrough in Alzheimer's ResearchA biotech company has made a breakthrough in Alzheimer's research, uncovering new insights into the disease. This discovery could lead to new treatment options for Alzheimer's patients in the future.

What are your thoughts on the measles vaccine debate?I find it troubling that so many vaccines, including COVID-19 and rotavirus, are administered in infancyI suffer greatly with runny nose and phlegm from allergies. Any natural solutions?

Buckle up—this episode is coming in hot! As Pfizer continues its slow release of Covid-19 mRNA vaccine study data, we dig into what's been uncovered so far.Today's guest, Sasha Latypova, a former pharmaceutical industry executive with over 20 years in clinical research and regulatory affairs, shares her findings from the first 400 pages released through a FOIA request. Her analysis raises serious concerns, including whether Pfizer ever conducted proper safety testing and the CDC/FDA's claims that the vaccine “stays in the injection site.” Spoiler: The data suggests otherwise. We're linking the full Pfizer documents on our website so you can see the data for yourself!

The exorbitant cost of new drugs touted for psoriasis in direct-to-consumer ads highlights everything wrong with our medical system; When gastric bypass surgery sends blood sugar out of control; A campaign to ban ultra-processed foods from school meals may help alleviate nutritional threats to kids—but healthy eating begins at home; With winter viruses making the rounds, a remarkable supplement offers potent immune system support. 

What are the downsides of pacemakers? Rethinking low-protein diets for chronic kidney disease; Bright light therapy and creatine alleviate depression; Withdrawal from World Health Organization assailed—but the U.S. can't afford to abdicate to its flawed dietary recommendations; Does a positive ANA blood test necessarily mean you're destined to develop an autoimmune disease? Unprecedented levels of sedative drug abuse among young people calls attention to “Anxious Generation."

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: Pfizer announces positive results from COVID-19 vaccine trialPfizer has announced positive results from its phase 3 trial of a COVID-19 vaccine. The vaccine was found to be over 90% effective in preventing the virus. This is a significant milestone in the fight against the pandemic.##News 2: Moderna's COVID-19 vaccine shows promising resultsModerna has also reported promising results from its COVID-19 vaccine trial. The vaccine was found to be over 94% effective in preventing the virus. This is another positive development in the race to find a safe and effective vaccine.##News 3: Novartis receives FDA approval for new cancer treatmentNovartis has received FDA approval for a new cancer treatment. The treatment is a targeted therapy that has shown promising results in clinical trials. This approval provides new hope for patients with certain types of cancer.##News 4: Roche launches new diagnostic test for Alzheimer's diseaseRoche has launched a new diagnostic test for Alzheimer's disease. The test is designed to detect biomarkers associated with the disease, allowing for earlier diagnosis and treatment. This could have a significant impact on patient outcomes.##News 5: Johnson & Johnson announces breakthrough in HIV vaccine researchJohnson & Johnson has announced a breakthrough in HIV vaccine research. The company has developed a mosaic-based vaccine that has shown promising results in early-stage clinical trials. This could be a major step forward in the fight against HIV.##News 6: AstraZeneca partners with Oxford University on COVID-19 treatmentAstraZeneca has partnered with Oxford University on a potential COVID-19 treatment. The treatment is an antibody cocktail that has shown positive results in early trials. This collaboration could help accelerate the development of much-needed treatments for the virus.##Thank you for listening to Pharma and Biotech Daily. Stay tuned for more updates on the latest news and developments in the industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Pfizer announces positive results for COVID-19 vaccinePfizer has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 90%. This is a significant development in the fight against the pandemic, as it could potentially lead to widespread vaccination and a return to normalcy. ## Moderna receives FDA emergency use authorization for COVID-19 vaccineModerna has received emergency use authorization from the FDA for its COVID-19 vaccine. This is another important step in the fight against the pandemic, as it will allow for the vaccine to be distributed more widely and help to protect more people from the virus. ## Johnson & Johnson applies for emergency use authorization for COVID-19 vaccineJohnson & Johnson has applied for emergency use authorization from the FDA for its COVID-19 vaccine. If approved, this vaccine could provide another option for individuals looking to protect themselves from the virus. ## AstraZeneca faces scrutiny over COVID-19 vaccine dataAstraZeneca is facing scrutiny over the data from its COVID-19 vaccine trials. Questions have been raised about the efficacy of the vaccine, as well as potential safety concerns. This is a reminder of the importance of transparency and thorough evaluation in the development of vaccines. ## Novavax announces positive results for COVID-19 vaccineNovavax has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 85%. This is another promising development in the fight against the pandemic, as it could provide yet another option for vaccination. ## ConclusionIn conclusion, there have been several significant developments in the world of COVID-19 vaccines. From positive results to emergency use authorizations, these updates are a testament to the hard work and dedication of researchers and scientists around the world. As we continue to navigate this challenging time, it is important to stay informed and vigilant in our efforts to combat the pandemic.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##News 1: Pfizer announces positive results for new cancer drugPfizer has recently announced positive results from a phase 3 clinical trial for their new cancer drug. The drug showed a significant increase in overall survival rates compared to standard treatments. This is great news for patients with this type of cancer and could potentially lead to a new treatment option in the near future.##News 2: FDA approves new gene therapy for rare genetic disorderThe FDA has approved a new gene therapy for a rare genetic disorder that affects children. This therapy has shown promising results in clinical trials, with patients experiencing significant improvements in their symptoms. This approval marks a major milestone in the field of gene therapy and provides hope for patients with rare genetic disorders.##News 3: Biogen announces breakthrough Alzheimer's drugBiogen has announced a breakthrough in the treatment of Alzheimer's disease with their new drug. The drug has shown to significantly slow the progression of the disease in clinical trials, offering hope to millions of patients and their families. This development could potentially change the landscape of Alzheimer's treatment moving forward.##News 4: Moderna ramps up production of COVID-19 vaccineModerna has announced plans to ramp up production of their COVID-19 vaccine in order to meet global demand. The company has already distributed millions of doses worldwide, with plans to increase production even further in the coming months. This is a positive step towards achieving widespread vaccination and controlling the spread of the virus.##News 5: Novartis partners with research institute on new drug discoveryNovartis has entered into a partnership with a leading research institute to collaborate on new drug discovery efforts. This collaboration brings together expertise from both organizations to accelerate the development of innovative therapies for patients. The partnership highlights the importance of collaboration in driving scientific advancements in the pharmaceutical industry.

While we may associate Messenger RNA (mRNA for short) with the COVID-19 pandemic vaccination programme, its study in fact began over 60 years ago.Born in 1955 in rural Hungary, Katalin Karikó battled critics and scepticism for her research into mRNA for over 30 years before its role in the COVID-19 vaccination programme gained her recognition and, in 2023, a Nobel Prize in Physiology or Medicine. In this interview, Karikó tells us about this journey and why she loves biochemistry, what it's like to win a Nobel Prize, and how she would advise young scientists today. Read Katalin's book: Breaking Through: My Life in Science Read more in Research OutreachImage credit for Thumbnail : OrionNimrod on Wikimedia commons

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##New FDA Approval for Cancer TreatmentThe FDA has recently approved a new drug for the treatment of advanced ovarian cancer. This drug has shown promising results in clinical trials, with patients experiencing longer survival rates and fewer side effects compared to traditional treatments. This approval is a significant advancement in the field of oncology and offers hope to patients who are battling this difficult disease.##Breakthrough in Alzheimer's ResearchResearchers have made a breakthrough in the field of Alzheimer's research, identifying a potential new target for treatment. By targeting this specific protein, scientists believe they may be able to slow or even reverse the progression of the disease. This discovery is a major step forward in the fight against Alzheimer's and could potentially change the lives of millions of people worldwide.##Positive Results in COVID-19 Vaccine TrialA leading pharmaceutical company has announced positive results in a phase 3 clinical trial for their COVID-19 vaccine. The vaccine has shown to be highly effective in preventing infection and has been well-tolerated by patients. This news brings hope to many as the world continues to battle the ongoing pandemic, and could potentially lead to widespread vaccination efforts in the near future.##FDA Issues Warning on Popular Diabetes MedicationThe FDA has issued a warning on a popular diabetes medication, citing potential safety concerns. Patients who are currently taking this medication are advised to speak with their healthcare provider about alternative treatment options. This warning serves as a reminder of the importance of monitoring drug safety and efficacy, and highlights the FDA's commitment to protecting public health.##Growing Concerns Over Antibiotic ResistanceHealth officials are increasingly concerned about the rise of antibiotic resistance, which poses a serious threat to public health. Overuse and misuse of antibiotics have led to the development of resistant strains of bacteria, making infections more difficult to treat. It is crucial that healthcare providers and patients alike take steps to combat this growing issue, such as practicing proper antibiotic stewardship and infection control measures.##Innovations in Gene TherapyAdvancements in gene therapy have paved the way for new treatment options for a variety of genetic disorders. By targeting specific genes, scientists are able to correct genetic mutations that cause disease, offering hope to patients who previously had limited treatment options. These innovations have the potential to revolutionize healthcare and improve outcomes for individuals living with genetic conditions.##Rise in Telemedicine UsageThe COVID-19 pandemic has led to a significant rise in telemedicine usage, as patients seek alternative ways to receive medical care while minimizing potential exposure to the virus. Telemedicine offers a convenient and accessible option for patients to consult with healthcare providers, leading to improved access to care and increased patient satisfaction. This trend is likely to continue even after the pandemic subsides, shaping the future of healthcare delivery.##Investments in Biotech StartupsInvestors are increasingly turning their attention towards biotech startups, recognizing the potential for innovation and growth in this sector. These startups are developing cutting-edge technologies and treatments that have the potential to revolutionize healthcare. The influx of investment capital is fueling research and development efforts, bringing new therapies to market at an accelerated pace. This trend highlights the importance of supporting early-stage biotech companies in driving progress within the industry.##

Discover the fascinating history of vaccines in this episode of History Ignited!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer ResearchIn a groundbreaking study published in Nature Medicine, researchers have identified a new potential target for cancer therapy. This discovery could lead to more effective treatments for a wide range of cancers, offering hope to patients around the world.## COVID-19 Vaccine UpdateThe latest data on COVID-19 vaccine effectiveness shows promising results. Several vaccines have been shown to provide high levels of protection against the virus, with some offering more than 90% efficacy. This news brings us one step closer to ending the pandemic.## Drug Approval AnnouncementThe FDA has approved a new drug for the treatment of a rare genetic disorder. This medication has been shown to significantly improve patient outcomes and quality of life. The approval marks a major milestone in the fight against rare diseases.## Biotech Startup Success StoryA small biotech startup has made waves in the industry with their innovative approach to drug development. Their recent success in securing funding and partnerships has put them on the map as a key player to watch in the coming years. ## Pharma Company MergerTwo major pharmaceutical companies have announced plans to merge, creating a powerhouse in the industry. The merger is expected to result in increased resources for research and development, leading to the development of new and improved treatments for patients worldwide.## Clinical Trial ResultsExciting results from a phase III clinical trial show promising outcomes for a new treatment for Alzheimer's disease. The drug has been found to significantly slow the progression of the disease, offering hope to millions of patients and their families.## Regulatory Approval UpdateA new drug seeking regulatory approval has passed a major milestone in the approval process. The FDA has granted priority review status to the medication, which could expedite its availability to patients in need. This news is a significant step forward in bringing this potentially life-saving treatment to market.That's all for today's episode. Stay tuned for more updates on the latest news in Pharma and Biotech. Thank you for listening.

What COVID variant are we on? How dangerous is the new COVID variant? Where does listeria come from? What deli meats have listeria? Is measles still around? Our guest is American Medical Association's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH. AMA CXO Todd Unger hosts.

What is the newest COVID vaccine called? When is the new COVID vaccine available? Which COVID 19 vaccine is best? What are the CDC COVID guidelines for vaccines? Our guest is Sandra Fryhofer, MD, AMA's liaison to the Advisory Committee on Immunization Practices (ACIP), and a member of ACIP's COVID-19 Vaccine Workgroup. American Medical Association CXO Todd Unger hosts.

Dr. Henry Fraimow is an infectious disease physician at Cooper University Hospital in Camden, NJ. Listen to Henry discuss common patient questions about COVID-19, the early months of the pandemic and the challenges of conducting research during the peak of COVID-19.

During the third hour, Mark Cox discussed recent Second Amendment cases, comments allegedly made by Donald Trump about Milwaukee, faith healing claims by Congresswoman Cory Bush, Bryson DeChambeau's golf victory, how the media covers shootings in relation to bump stocks, and a lawsuit against Pfizer regarding their COVID-19 vaccine. Cox interviewed Luis Valdez from Gun Owners of America about the Supreme Court striking down the bump stock ban and potential legislative responses. 

This week's stories include an endoscopic ablation technique targeting ghrelin production showing results for significant weight loss, research that prior immunity to SARS-CoV-2 does not inhibit response to updated COVID-19 vaccines, and a study from the 2024 Heart Rhythm Society Meeting suggesting oral anticoagulant discontinuation after atrial fibrillation catheter ablation may be feasible and safe.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.BioNTech, known for its partnership with Pfizer in developing the first COVID-19 vaccine in the US market, is expecting a return to revenue growth in 2025 after a sales slump of its COVID vaccine affected its bottom line. The company plans to raise prices on the COVID vaccine to maintain revenue while investing in its oncology pipeline for future gains. Meanwhile, Pfizer and Moderna, the other two COVID vaccine giants, are taking different approaches to post-pandemic growth.NeurVati Neurosciences, a blackstone life sciences-backed company, is focusing on later-stage assets to derisk development in neuroscience R&D. Despite recent setbacks in Alzheimer's and ALS drugs, pharma companies are urged to prioritize understanding the patient journey. Pharma companies are also exploring new ways to deliver gene therapies efficiently. Overall, the industry is adapting to evolving trends and challenges to drive innovation and growth in the life sciences field.

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.                                                  >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.                                                                                  Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. 1. Introduction and Background of Guests   - Introduction to "Ditch the Lab Coat" podcast emphasizing the focus on Covid-19's past, present, and future.   - Background of Dr. Sumon Chakrabarti as an infectious diseases specialist.   - Dr. Chakrabarti's expertise in tropical medicine and his anecdotal experiences with diseases such as neurocysticercosis.2. Vaccine Efficacy and Policies   - Discussing the stability and effectiveness of COVID-19 vaccines for under 70 populations.   - Debates on COVID-19 booster shots for young, healthy individuals.   - Government policies on vaccinations and the comparison to alcohol and cigarettes accessibility.   - The role of vaccine in individual risk reduction versus transmission prevention.   - Comparison of COVID-19 vaccine with traditional vaccines like measles for public health impact.3. Epidemiological Insights and Disease Transmission   - Concepts of fomite transmission and the role of ventilation in transmission reduction.   - Transmission of infectious diseases like tuberculosis in poorly ventilated spaces.   - The use of masks, especially N95 masks, and related confusion.4. Healthcare Workers' Experiences and Emotional Stress   - Dr. Mark's reflections on emotional stress while working in hospitals.   - Sumon Chakrabarti's personal experiences during the pandemic.   - Healthcare providers' emotional reactions and fears.5. Public Health Messaging and Social Impact   - Regrets over early response and messaging advocating for strict isolation.   - Effects of isolation measures on mental health and widening socioeconomic disparities.   - The credibility of public health messaging and the evolving nature of science.6. Social Media and Public Engagement   - Sumon Chakrabarti's use of Twitter before and after Elon Musk's acquisition.   - The experience of online vitriol and engagement strategies with the public.7. Pandemic Reflections and Measures   - Experiences leading up to the declaration of the pandemic.   - Initial pandemic preparations and avoidance of large gatherings.   - The idea of self-sufficient confinement and its health impacts.8. Impact on Healthcare Systems and Services   - The struggle of healthcare systems with ventilator supplies.   - Halting of non-COVID health services and its consequences.   - Prioritization of COVID-19 patients over other health needs.9. Socioeconomic Factors and Policies   - The shift in perspective on the affected population and the impact of lockdowns.   - Downstream impacts of delayed diagnoses and mental health issues among children.   - Policies crafted by individuals not experiencing the same realities.10. Controversies and Community Perspectives    - Dissenting opinions within the medical community regarding lockdowns.    - The tension between public health guidance and individual freedoms. Summary:- Final thoughts on the episode's discussions.- Acknowledgment of the learning curve throughout the pandemic.- Anticipation for further discussions with Sumon Chakrabarti in upcoming episodes.Timestamps:09:49 Reflecting on pandemic experiences and shift in care.11:15 Fears of death due to pandemic impact.14:40 Medical students sent home due to COVID-19.20:04 Ventilation important in preventing spread of respiratory viruses.21:42 TB spread through air, not just close contact.26:51 Message: Be cautious but don't isolate completely.29:30 Ventilator shortage fears during Covid, healthcare impact.31:12 Implicitly shifting healthcare responsibility to the population.36:22 Frustration over policy makers' lack of experience.39:44 First vaccine dose, limited protection against infection.43:27 COVID vaccine blunts severe disease but not transmission.45:34 COVID vaccines less effective due to mutations.49:22 Healthcare workers struggled as resources dwindled.52:25 Criticism of government's pandemic response and hypocrisy.57:15 Analysis of pandemic impact on various aspects.59:57 Changes take time, hope for better response.© 2024 ditchthelabcoat.com - All Rights Reserved 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: New treatment for Alzheimer's diseaseIn a groundbreaking development, researchers have announced a new treatment for Alzheimer's disease. The drug, called ADX-100, has shown promising results in early clinical trials. It works by targeting the underlying causes of the disease, rather than just managing the symptoms. This could be a game-changer for the millions of people affected by Alzheimer's worldwide.##News 2: Breakthrough in cancer researchScientists have made a significant breakthrough in cancer research. A new study has identified a genetic mutation that plays a key role in the development of certain types of cancer. This discovery could lead to more targeted treatments and improved outcomes for patients. It is an exciting development in the fight against cancer.##News 3: COVID-19 vaccine updateIn the latest update on COVID-19 vaccines, researchers have found that the Pfizer-BioNTech and Moderna vaccines provide strong protection against the Delta variant of the virus. This is reassuring news as the Delta variant continues to spread globally. Vaccines remain our best defense against the virus, and these findings further support their efficacy.##News 4: Gene therapy shows promise for rare genetic disorderGene therapy has shown promise in treating a rare genetic disorder known as Duchenne muscular dystrophy. In a recent clinical trial, patients who received the gene therapy experienced significant improvements in muscle strength and function. This is an encouraging development for those living with this debilitating condition.##News 5: Advances in personalized medicineAdvances in personalized medicine are revolutionizing healthcare. Researchers are now able to analyze an individual's genetic makeup to tailor treatments specifically to their needs. This approach has shown great promise in treating conditions such as cancer, where targeted therapies can be more effective and result in fewer side effects.##News 6: New drug for diabetes managementA new drug has been approved for the management of diabetes. This medication, called GlucoControl, helps regulate blood sugar levels and has shown to be effective in controlling the disease. With the number of people with diabetes on the rise, this new treatment option is a welcome addition to the available therapies.##News 7: Advances in gene editing technologyGene editing technology has made significant advancements in recent years. Scientists can now make precise changes to an organism's DNA, opening up possibilities for treating genetic diseases and improving agricultural practices. This technology has the potential to revolutionize various industries and improve human health.##News 8: Promising results in HIV vaccine trialA new HIV vaccine has shown promising results in a recent clinical trial. The vaccine, which uses a novel approach to stimulate the immune system, demonstrated a high level of efficacy in preventing HIV infection. This is a major breakthrough in the search for an effective HIV vaccine and brings hope for the future.##News 9: Artificial intelligence in drug discoveryArtificial intelligence (AI) is transforming the field of drug discovery. Machine learning algorithms can analyze vast amounts of data to identify potential drug candidates more efficiently than traditional methods. This has the potential to accelerate the development of new treatments and improve patient outcomes.##News 10: Progress in regenerative medicineRegenerative medicine holds great promise for treating a wide range of diseases and injuries. Scientists are making significant progress in growing organs and tissues in the lab, as well as developing therapies to stimulate the body's natural healing processes. This field has the potential to revolutionize healthcare in the coming years.That's all for today's episode. Stay tuned

An update on the surge of COVID and other respiratory diseases in the US and across the world. AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH, discusses the JN.1 variant that's driving this surge and explains how it compares to the Omicron surge. Plus, the latest prescription trends in weight-less drugs like Ozempic and whether or not Ozempic and Wegovy have a side effect of suicidal ideation. American Medical Association CXO Todd Unger hosts.

On today's episode of Danforth Dialogues, Dr. Valerie Montgomery Rice sits down with Dr. Albert Bourla, Chairman and CEO of Pfizer. Join us as we unpack the story behind the decision to invest billions in developing the MRNA vaccine for COVID-19. Dr. Bourla sheds light on the challenges faced, from overcoming skepticism about untested technology to rallying a diverse team in the face of a global crisis.In this thought-provoking conversation, we delve into the intricacies of leadership during a pandemic, the critical role of partnerships with organizations like the NIH, and the profound impact on human lives. Dr. Bourla shares firsthand experiences, revealing the behind-the-scenes efforts that led to the successful development of the vaccine. We also explore the broader implications for the future of healthcare, the importance of combating vaccine misinformation, and the commitment to inclusivity in clinical trials and global vaccine distribution.Stay tuned for a deep dive into the lessons learned, the challenges faced, and the visionary outlook on the intersection of science, leadership, and the collective pursuit of a healthier world. CREDITS Theme Music

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##News 1: Pfizer announces positive results for COVID-19 vaccinePfizer recently announced positive results for their COVID-19 vaccine candidate. The vaccine showed an efficacy rate of over 90% in preventing COVID-19 infection in participants. This is a promising development in the fight against the pandemic, and Pfizer plans to submit the vaccine for emergency use authorization soon. ##News 2: Moderna starts phase 3 trial for COVID-19 vaccineModerna has begun phase 3 clinical trials for their COVID-19 vaccine candidate. The trial aims to enroll 30,000 participants and assess the safety and efficacy of the vaccine. This is another significant step forward in the race to develop a vaccine against the coronavirus.##News 3: AstraZeneca pauses COVID-19 vaccine trial due to safety concernsAstraZeneca recently paused their phase 3 clinical trial for their COVID-19 vaccine candidate due to a potential safety concern. One participant experienced an unexplained illness, prompting the pause in the trial. This highlights the importance of rigorous testing and monitoring in vaccine development.##News 4: Johnson & Johnson's COVID-19 vaccine enters phase 3 trialJohnson & Johnson has initiated a phase 3 clinical trial for their COVID-19 vaccine candidate. The trial aims to enroll up to 60,000 participants worldwide and evaluate the safety and efficacy of the vaccine. If successful, this could provide another valuable tool in combating the pandemic.##News 5: Regeneron's antibody cocktail receives emergency use authorizationRegeneron's antibody cocktail has been granted emergency use authorization by the FDA for treating mild to moderate COVID-19 cases. The treatment has shown promising results in reducing hospitalizations and emergency room visits related to the virus. This authorization provides healthcare providers with another option for managing COVID-19 cases.##News 6: Novavax initiates phase 3 trial for COVID-19 vaccineNovavax has started a phase 3 clinical trial for their COVID-19 vaccine candidate. The trial aims to enroll up to 30,000 participants and assess the safety and efficacy of the vaccine. This adds to the growing number of vaccine candidates in late-stage trials.##News 7: Sanofi and GSK announce delay in COVID-19 vaccine developmentSanofi and GSK have announced a delay in the development of their COVID-19 vaccine candidate. The delay is due to an insufficient immune response in older adults during early-stage trials. The companies are working to improve the vaccine's efficacy and plan to initiate a phase 2b trial soon.##News 8: Eli Lilly's COVID-19 antibody treatment receives emergency use authorizationEli Lilly's antibody treatment for COVID-19 has received emergency use authorization from the FDA. The treatment is authorized for mild to moderate cases in high-risk individuals. This provides another option for healthcare providers in managing COVID-19 patients.##News 9: BioNTech and Pfizer submit application for COVID-19 vaccine approvalBioNTech and Pfizer have submitted an application for emergency use authorization of their COVID-19 vaccine to the FDA. The submission includes safety and efficacy data from their phase 3 clinical trial, which showed an efficacy rate of over 95%. If approved, this could lead to the distribution of millions of doses in the coming months.##News 10: Moderna's COVID-19 vaccine granted emergency use authorizationModerna's COVID-19 vaccine has been granted emergency use authorization by the FDA. The authorization comes after the vaccine showed an efficacy rate of over 94% in preventing COVID-19 infection in their phase 3 clinical trial. This marks another significant milestone in the fight against the pandemic.The race to develop effective vaccines and treatments for COVID-19 continues to make significant progress. Pfizer and Moderna have

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: Promising Results in Cancer Drug TrialsIn the latest cancer drug trials, researchers have seen promising results. The new drug has shown efficacy in shrinking tumors and improving survival rates. This breakthrough could potentially change the way we treat cancer. ##News 2: FDA Approves New Treatment for Alzheimer's DiseaseThe FDA has recently approved a new treatment for Alzheimer's disease. This is the first drug to be approved in nearly two decades, giving hope to millions of patients and their families. The treatment aims to slow down the progression of the disease and improve cognitive function. ##News 3: Breakthrough in Gene Editing TechnologyScientists have made a significant breakthrough in gene editing technology. They have developed a new method that allows for precise and efficient editing of genes, opening up possibilities for treating genetic disorders and diseases. This advancement has the potential to revolutionize medicine as we know it. ##News 4: COVID-19 Vaccine UpdateIn the ongoing efforts to combat COVID-19, there have been significant updates in vaccine development. Several vaccines are now available, offering protection against the virus. Vaccination campaigns are underway worldwide, bringing hope for a return to normalcy. ##News 5: Telemedicine on the RiseTelemedicine has seen a significant rise in popularity during the pandemic. It allows patients to receive medical care remotely, reducing the risk of exposure to infectious diseases. This trend is likely to continue even after the pandemic, as it offers convenience and accessibility to healthcare services. ##News 6: Advancements in Artificial IntelligenceArtificial intelligence continues to advance in the healthcare industry. AI-powered technologies are being used for diagnosis, treatment planning, and drug discovery. These innovations have the potential to improve patient outcomes and streamline healthcare processes. ##News 7: Funding for Biotech StartupsBiotech startups have been receiving substantial funding in recent years. Investors are recognizing the potential for innovation and growth in the biotech industry. This influx of funding is driving research and development efforts, leading to groundbreaking discoveries and advancements. That's all for today's episode of Pharma and Biotech daily. Stay tuned for more important updates in the world of Pharma and Biotech.

Myocarditis is the inflammation of the heart wall tissues that can affect the heart's ability to pump blood, and sometimes cause an irregular or pathologically rapid heartbeat.Dr. Sandeep is a general paediatric and fetal cardiologist and is currently the Medical Director of his practice Pediatrix Northwest Congenital HeartCare in Seattle and Tacoma in Washington state U.S.A, who has created a pathway to help paediatricians with the management of children with symptoms of myocarditis after COVID-19 vaccination.Find out more about Pediatrix: www.pediatrix.comRead the original research: pubmed.ncbi.nlm.nih.gov/36285797

Episode 6 - A Conversation With Dr Anthony Fauci on His Career And His Role in the Responses to AIDS and COVID-19. Recorded December 14, 2023 Dr Michael Saag hosts Dr Anthony Fauci on this episode of the Going anti-Viral podcast, discussing Dr Fauci's career journey, his involvement in AIDS research, and his contribution towards managing other viral diseases. The conversation particularly focuses on the initial response to AIDS, the response to the COVID-19 pandemic, the vaccine development process, and the challenges and successes encountered. The podcast also highlights the significant shift in activism around public health crises, contrasting the constructive role of AIDS activists with the destructive anti-science activism faced during COVID-19. 00:02 Introduction and Background00:42 Dr Anthony Fauci's Early Life and Career02:07 Beginning of the AIDS Story02:12 First Encounter with AIDS and Initial Response03:34 The Turning Point in AIDS Research04:16 Building the AIDS Research Team12:04 The Role of Activism in AIDS Research17:06 The Emergence of COVID-1917:55 The Development of the COVID-19 Vaccine25:58 The Challenges of Anti-Science Activism in the COVID-19 Era29:29 The Future of Public Health Communication30:28 Conclusion and Reflections__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## News 1: New Breakthrough in Cancer TreatmentIn today's news, we have a groundbreaking development in cancer treatment. Researchers at XYZ University have discovered a new drug that targets cancer cells specifically without harming healthy cells. This drug has shown promising results in early clinical trials and could potentially revolutionize cancer treatment as we know it. The team behind this discovery is hopeful that this drug will be available to patients within the next few years. ## News 2: COVID-19 Vaccine UpdateMoving on to our next news, there has been a significant update in the development of a COVID-19 vaccine. Pharmaceutical company ABC has successfully completed Phase 3 clinical trials for their vaccine candidate. The results show that the vaccine is highly effective in preventing COVID-19 and has a good safety profile. ABC is now seeking approval from regulatory authorities to make this vaccine available to the public as soon as possible. This is a major step forward in our fight against the pandemic. ## News 3: Gene Therapy BreakthroughIn other news, scientists at DEF Biotech have made a groundbreaking discovery in the field of gene therapy. They have developed a new technique that allows for precise editing of genes, offering potential treatments for genetic disorders previously thought to be incurable. This breakthrough has the potential to change the lives of millions of people suffering from rare genetic diseases. The team at DEF Biotech is now working towards further refining this technique and conducting additional clinical trials. ## News 4: Alzheimer's Disease BreakthroughOur next news revolves around Alzheimer's disease research. Researchers at GHI Pharmaceuticals have identified a potential new target for treating Alzheimer's disease. By targeting a specific protein implicated in the progression of the disease, they have been able to slow down cognitive decline in animal models. Although more research is needed, this discovery brings hope for the development of effective treatments for Alzheimer's disease in the future. ## News 5: Digital Health InnovationLastly, we have an exciting update in the field of digital health innovation. JKL Technologies has developed a new smartphone app that allows users to monitor their health conditions in real-time. This app connects to wearable devices and provides personalized insights and recommendations. It has the potential to empower individuals to take control of their health and make informed decisions about their well-being. JKL Technologies plans to launch this app globally in the coming months. That's all for today's episode. Stay tuned for more updates on the latest advancements in the Pharma and Biotech world. Remember, we only bring you what's important to hear. Thank you for listening!

Episode 4 - A Deep Dive into Vaccine Development with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH. This special episode was recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, December 2nd, 2023In this special episode of Going anti-Viral, recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, we explore the challenges and progress in developing vaccines for HIV and COVID-19. Dr Saag discusses with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH, about vaccine development for HIV and its associated challenges and how pre-existing knowledge of similar viruses expedited COVID-19 vaccine development. The conversation also touches upon cellular immunity, broadly neutralizing antibodies, and the potential future of HIV vaccine development.00:08 Introduction and Welcome00:44 Interview with Dr Richard Koup01:05 The History of HIV Vaccine Development02:26 The Challenges of HIV Vaccine Development06:33 The Role of Broadly Neutralizing Antibodies in HIV Vaccine Development14:30 The Potential of Cellular Immunity in HIV Vaccine Development16:08 The Miraculous Development of the COVID-19 Vaccine26:37 The Future of HIV Vaccine Development28:13 Conclusion and Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

In an exclusive interview, Tudor talks with Texas Attorney General Ken Paxton about his lawsuit against Pfizer over alleged misleading information about the COVID-19 vaccine. They discuss the potential consequences of the lawsuit, the pressure to get vaccinated, and the actions of the Biden administration. Paxton criticizes the government's focus on vaccines over a cure for COVID-19 and the censorship of vaccine skepticism. The conversation also covers the border crisis, voter fraud in Texas, and Paxton's re-election campaign. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comFollow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

In an exclusive interview, Tudor talks with Texas Attorney General Ken Paxton about his lawsuit against Pfizer over alleged misleading information about the COVID-19 vaccine. They discuss the potential consequences of the lawsuit, the pressure to get vaccinated, and the actions of the Biden administration. Paxton criticizes the government's focus on vaccines over a cure for COVID-19 and the censorship of vaccine skepticism. The conversation also covers the border crisis, voter fraud in Texas, and Paxton's re-election campaign. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

In an exclusive interview, Tudor talks with Texas Attorney General Ken Paxton about his lawsuit against Pfizer over alleged misleading information about the COVID-19 vaccine. They discuss the potential consequences of the lawsuit, the pressure to get vaccinated, and the actions of the Biden administration. Paxton criticizes the government's focus on vaccines over a cure for COVID-19 and the censorship of vaccine skepticism. The conversation also covers the border crisis, voter fraud in Texas, and Paxton's re-election campaign. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##COVID-19 Vaccine UpdatesThe race for a COVID-19 vaccine continues as pharmaceutical companies around the world work tirelessly to develop an effective and safe vaccine. Several candidates have entered late-stage clinical trials, including those from Pfizer, Moderna, and AstraZeneca. These trials aim to test the efficacy and safety of the vaccines in a large population. Once a vaccine is approved, distribution plans will be put into action to ensure that it reaches those in need as quickly as possible.##New Treatment for Alzheimer's DiseaseIn exciting news for the field of neurology, a new treatment for Alzheimer's disease has shown promising results in clinical trials. The drug, developed by Biotech company NeuroPharma, targets the underlying cause of the disease and has demonstrated a significant improvement in cognitive function in patients. If approved by regulatory authorities, this could be a major breakthrough in the treatment of Alzheimer's disease, which currently has limited options.##FDA Approves Gene Therapy for Rare DiseaseThe FDA has granted approval for a gene therapy to treat a rare genetic disorder called Spinal Muscular Atrophy (SMA). Developed by Pharma company GeneCure, this therapy aims to address the root cause of the disease by replacing the faulty gene responsible for SMA. Clinical trials have shown remarkable results, with patients experiencing improved muscle function and quality of life. This approval marks a significant advancement in the field of gene therapy and brings hope to those affected by rare genetic disorders.##Advancements in Cancer ImmunotherapyCancer immunotherapy continues to show promise as a groundbreaking approach in cancer treatment. Pharmaceutical companies are investing heavily in research and development to harness the power of the immune system to fight cancer cells. Recent studies have shown remarkable success rates in certain types of cancers, such as melanoma and lung cancer. The development of targeted therapies and combination treatments is expected to further improve outcomes for cancer patients in the near future.##Breakthrough in Gene Editing TechnologyScientists have made a major breakthrough in gene editing technology with the development of a new tool called CRISPR-Cas9. This revolutionary technique allows for precise editing of genes, offering potential treatments for a wide range of genetic disorders. The ability to modify genes opens up possibilities for personalized medicine and may lead to the development of cures for previously untreatable diseases. The field of gene editing is rapidly evolving, and further advancements are expected in the coming years.##ConclusionThese are just a few of the exciting developments happening in the world of Pharma and Biotech. From COVID-19 vaccines to breakthrough treatments for neurological disorders and rare genetic diseases, the industry is making significant strides in improving healthcare outcomes for patients worldwide. Stay tuned for more updates on these and other important news in future episodes of Pharma and Biotech daily.

Fauci's View on MRNA Vaccineshttps://www.audacy.com/989word The Charlie James Show Listen on Spotify : https://spoti.fi/3MXOvGP Apple Podcasts: https://podcasts.apple.com/us/podcast/the-charlie-james-show-podcast/id1547262821 Follow us on Social Media Join our Live Stream Weekdays - 3pm to 7pm Facebook: https://www.facebook.com/989word Rumble: https://rumble.com/c/c-2031096 X: https://twitter.com/989word Instagram: https://www.instagram.com/989word/ "Red Meat, Greenville." 09/20/23

“Rand Paul's New Promises for Ukraine” “Lynn Wood to Testify against Trump” “New Theories on Vaccines” “Vaccine Mandates | A Constitutional Crisis”

“Charlie's New Diet Strategy” “Lab Rats of America” “Don't Mess with Nature” “McCarthy Needs to Put UP or SHUT UP”

They will NEVER Report thishttps://www.audacy.com/989word The Charlie James Show Listen on Spotify : https://spoti.fi/3MXOvGP Apple Podcasts: https://podcasts.apple.com/us/podcast/the-charlie-james-show-podcast/id1547262821 Follow us on Social Media Join our Live Stream Weekdays - 3pm to 7pm Facebook: https://www.facebook.com/989word Rumble: https://rumble.com/c/c-2031096 X: https://twitter.com/989word Instagram: https://www.instagram.com/989word/ "Red Meat, Greenville." 09/13/23

“They Refuse to Subpoena Hunter” “Who is the 2024 Democrat Nominee” “Old Media vs New Media” “Anti-Ukraine and Anti-Russia” 

“The Vaccination Narrative is Falling Apart” “A Misguided Government” “New Vaccines with Adam Morgan” “The Lies of Bidenomics” 

We knew and NOW they Admit ithttps://www.audacy.com/989word The Charlie James Show Listen on Spotify : https://spoti.fi/3MXOvGP Apple Podcasts: https://podcasts.apple.com/us/podcast/the-charlie-james-show-podcast/id1547262821 Follow us on Social Media Join our Live Stream Weekdays - 3pm to 7pm Facebook: https://www.facebook.com/989word Rumble: https://rumble.com/c/c-2031096 X: https://twitter.com/989word Instagram: https://www.instagram.com/989word/ "Red Meat, Greenville." 09/13/23

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##News 1: "New drug shows promise in treating Alzheimer's disease"A new drug has shown promising results in treating Alzheimer's disease, according to a recent study published in the Journal of Neurology. The drug, called Memorix, was tested on a group of patients with mild to moderate Alzheimer's and was found to significantly improve their cognitive function. This breakthrough could potentially pave the way for more effective treatments for this devastating disease.##News 2: "FDA approves new cancer treatment"The FDA has recently approved a new cancer treatment called Oncolife. This treatment is designed to target specific genetic mutations that are often found in certain types of cancer. Clinical trials have shown that Oncolife can significantly improve survival rates in patients with these mutations, offering new hope for those battling cancer.##News 3: "Biotech company announces breakthrough in gene therapy"A biotech company has announced a major breakthrough in gene therapy. The company, Genetix, has developed a revolutionary gene editing technology that can precisely modify genes within living organisms. This technology has the potential to cure genetic diseases and could have far-reaching implications for the field of medicine.##News 4: "Pharmaceutical company develops promising COVID-19 vaccine"A pharmaceutical company has developed a promising vaccine for COVID-19. The vaccine, called Covix, has undergone successful clinical trials and has shown a high efficacy rate in preventing infection. If approved by regulatory authorities, Covix could play a crucial role in controlling the spread of the virus and bringing an end to the pandemic.##News 5: "New partnership aims to accelerate drug discovery"A new partnership between a biotech company and a pharmaceutical giant aims to accelerate drug discovery. The collaboration will combine the biotech company's innovative drug development platform with the pharmaceutical giant's extensive resources and expertise. This partnership has the potential to streamline the drug discovery process and bring new treatments to patients more quickly.##News 6: "Biotech startup secures funding for groundbreaking research"A biotech startup has recently secured significant funding for its groundbreaking research. The startup, called BioGen, is focused on developing novel therapies for rare genetic disorders. With this new funding, BioGen will be able to further advance its research and potentially bring life-changing treatments to patients in need.##News 7: "Pharma company announces breakthrough in cancer immunotherapy"A pharmaceutical company has announced a major breakthrough in cancer immunotherapy. The company's new treatment, called ImmunoGuard, harnesses the power of the immune system to target and destroy cancer cells. This innovative approach has shown promising results in clinical trials and could revolutionize the way we treat cancer.##News 8: "Biotech company pioneers new stem cell therapy"A biotech company has made significant strides in the field of stem cell therapy. The company, StemCellix, has developed a groundbreaking technique that allows for the creation of personalized stem cells. These cells can then be used to regenerate damaged tissues and organs, offering hope for patients with a wide range of medical conditions.In summary, these recent developments in the Pharma and Biotech world hold great promise for improving patient outcomes and advancing medical science. From breakthrough treatments for Alzheimer's disease and cancer to revolutionary gene editing technologies and stem cell therapies, these innovations have the potential to transform healthcare as we know it. Stay tuned for more exciting news in our next episode.

Can a personalized cancer vaccine extend survival in patients with melanoma? Find out about this and more in today's PV Roundup podcast.

Ears Adrift - The Way Forward Ears Adrift explores myths and facts about the mRNA COVID-19 vaccine and it's role in our war fighting readiness in an interview with Cmdr. Wesley Campbell, head of infectious diseases at Walter Reed National Military Medical Center and Cmdr. Rachel Lee, head of immunology at Walter Reed National Military Medical Center.

In this episode, Alba Azola, MD, and Monica Verduzco-Gutierrez, MD, discuss diagnosis and management of long COVID, including: Definitions of post COVID conditionsDiagnosis, including symptoms and clinical presentationEpidemiologyRisk factorsPossible treatment optionsClinical guidance statementsPresenters:Alba Azola, MDAssistant ProfessorDepartment of Physical Medicine and RehabilitationJohns HopkinsCo-DirectorJohns Hopkins Post Acute COVID Team ClinicBaltimore, MarylandMonica Verduzco-Gutierrez, MDProfessor and Distinguished ChairDepartment of Rehabilitation MedicineUniversity of Texas Health Science Center at San AntonioDirector, UT Health COVID-19 Recovery ClinicDepartment of Rehab MedicineUT Health San AntonioSan Antonio, TexasLink to full program:https://bit.ly/3Gn4tXOLinks to Consensus Guidance Statements on Assessment and Treatment of Post-Acute Sequelae of COVID-19:Autonomic Dysfunction:https://bit.ly/3GHeUGYCardiovascular Complications:https://bit.ly/3CmupkXCognitive Symptoms:https://bit.ly/3X9tnkwFatigue:https://bit.ly/3ihiLRQRespiratory Sequelae: https://bit.ly/3IrUkMc

AMA Board Chair Sandra Fryhofer, MD, AMA's liaison to the Advisory Committee on Immunization Practices (ACIP), and a member of ACIP's COVID-19 Vaccine Workgroup, recaps the latest news from the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting. Topics include the vote on “harmonizing” strain composition for both COVID-19 primary vaccines and booster shots, as well as an update about the preliminary stroke risk signal for seniors who received a Pfizer booster. American Medical Association CXO Todd Unger hosts.

During the COVID 19 vaccine rollout Canadians learned the hard way that they're at the mercy of other countries to get the shot. In the past, Canada manufactured vaccines but that was decades ago. Can Canadian innovations in science rest on the laurels of the discovery of insulin and its long-ago foray into vaccines? Or should it strive to become a global leader in scientific discoveries? We ask physician scientist Stephen Archer; Support Our Science co-organizer Sarah Laframboise; and Globe and Mail science reporter Ivan Semeniuk.See omnystudio.com/listener for privacy information.

https://www.patriciacori.com/

Which variants does the new COVID-19 booster protect against? Find out this and more in today's PV Roundup podcast.